A review of hemp as food and nutritional supplement

P Cerino, C Buonerba, G Cannazza… - Cannabis and …, 2021 - liebertpub.com
The term “hemp” refers to Cannabis sativa cultivars grown for industrial purposes that are
characterized by lower levels of tetrahydrocannabinol (THC), the active principle responsible …

Toll-like receptors and COVID-19: a two-faced story with an exciting ending

…, V Margherita, SD Placido, C Buonerba - Future science …, 2020 - Future Science
Coronavirus disease 19 (COVID-19) is caused by a novel single-stranded RNA beta-coronavirus
called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. COVID-19 …

Liquid biopsy in bladder cancer: State of the art and future perspectives

…, M Ferro, GM Busetto, E La Civita, C Buonerba… - Critical Reviews in …, 2022 - Elsevier
Bladder cancer is the most common malignancy of the urinary tract. Cystoscopy represents
the gold standard in the diagnosis of suspicious bladder lesions. However, the procedure is …

[HTML][HTML] Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 …

…, G Perruolo, V D'Esposito, V Cosimato, C Buonerba… - PloS one, 2013 - journals.plos.org
Many efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment
have been made. To this aim, Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) …

Toxicities of targeted therapy and their management in kidney cancer

…, M Staehler, S Joniau, F Montorsi, C Buonerba - European urology, 2011 - Elsevier
CONTEXT: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been
evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and …

A comprehensive outlook on intracerebral therapy of malignant gliomas

C Buonerba, G Di Lorenzo, A Marinelli… - Critical reviews in …, 2011 - Elsevier
Glioblastoma multiforme (GBM) is the most frequent and aggressive malignant glioma (MG),
with a median survival time of 12–15 months, despite current best treatment based on …

Castration-resistant prostate cancer: current and emerging treatment strategies

G Di Lorenzo, C Buonerba, R Autorino, S De Placido… - Drugs, 2010 - Springer
Until very recently, docetaxel was the only approved agent in castration-resistant prostate
cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, …

Immunotherapy for the treatment of prostate cancer

G Di Lorenzo, C Buonerba, PW Kantoff - Nature reviews Clinical …, 2011 - nature.com
Failure of immune surveillance has a prominent role in tumorigenesis. Cancerous cells can
evade T-cell responses to tumor-associated antigens by multiple mechanisms. Active …

[HTML][HTML] Liquid biopsy biomarkers in urine: a route towards molecular diagnosis and personalized medicine of bladder cancer

…, A Liotti, M Cennamo, F Tortora, C Buonerba… - Journal of personalized …, 2021 - mdpi.com
Bladder cancer (BC) is characterized by high incidence and recurrence rates together with
genomic instability and elevated mutation degree. Currently, cystoscopy combined with …

Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis

G Di Lorenzo, C Buonerba, P Federico… - BJU …, 2012 - Wiley Online Library
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? Metastatic or locally advanced squamous cell carcinoma of the …